Yan Long
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan Long has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Yonggang Zhang
A Department of Clinical Laboratory , Central Hospital of Longhua New District , Shenzhen , China
3 shared publicationsHongling Yang
B Department of Clinical Laboratory , Guangzhou Women & Children Medical Center, Guangzhou Medical University , Guangzhou , China
2 shared publicationsChen Zhou
Laboratory Department, Guangzhou Women and Children Medical Center, Guangzhou Medical University, Guangzhou, China
1 shared publicationGuoqing Huang
A Department of Clinical Laboratory , Central Hospital of Longhua New District , Shenzhen , China
1 shared publicationHong-Ling Yang
Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China
1 shared publication- Hongling Yang
Department of Clinical Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China
1 shared publication
Latest Publications
- 1 October 2018
- Published by Elsevier in Pregnancy Hypertension
- Vol. 14, 43-48
Pigment epithelium–derived factor/vascular endothelial growth factor ratio for early prediction of preeclampsia: A prospective multicenter study in China
- 1 October 2018
- Published by Elsevier in Pregnancy Hypertension
- Vol. 14, 43-48
Pigment epithelium–derived factor/vascular endothelial growth factor ratio for early prediction of preeclampsia: A prospective multicenter study in China
- 17 February 2017
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 39 (2) , 108-113
MiR-942 decreased before 20 weeks gestation in women with preeclampsia and was associated with the pathophysiology of preeclampsia in vitro
Objective: To investigate the possible relationship between miR-942 levels and the pathogenesis of preeclampsia using in vitro assays and to investigate circulating miR-942 levels in the early phase of mid-of pregnancy in women who later developed preeclampsia and in women with uncomplicated pregnancies. Methods: Plasma samples were collected from pregnant women between 12 and 20 weeks of gestation. MiR-942 levels were determined by stem-loop real-time PCR for 26 cases who subsequently developed preeclampsia as well as for 52 controls. Bioinformatics software was used to predict the target genes of miR-942, and a dual-luciferase reporter system was utilized to validate target gene regulation. Finally, MTT proliferation assays, transwell invasion assays, and endothelial cell tube formation assays were performed to further explore the function of miR-942 using a human extravillous trophoblast cell line (TEV-1). Result: Circulating miR-942 levels were significantly lower in mid-pregnancy (12–20 weeks gestation) in women who later developed preeclampsia compared with those with an uncomplicated pregnancy (p < 0.05). Endoglin (ENG) is an miR-942 target gene. MiR-942 had a sensitivity of 0.673, a specificity of 0.875, and an area under the receiver operating characteristic curve (AUC) of 0.718 [95% CI, 0.594–0.822] for the possible screening of preeclampsia. In vitro, decreased miR-942 expression decreased the invasive ability of TEV-1 cells, and inhibited the HUVEC angiogenesis assay, both effects that are similar to what is observed in preeclampsia (both p Conclusion: MiR-942 may be involved in the pathogenesis of preeclampsia via the regulation of its target gene ENG. Multicenter studies must be performed and a greater number of samples must be analyzed to ascertain whether circulating miR-942 levels can serve as a novel early diagnostic marker for preeclampsia.
- 17 February 2017
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 39 (2) , 108-113
MiR-942 decreased before 20 weeks gestation in women with preeclampsia and was associated with the pathophysiology of preeclampsia in vitro
Objective: To investigate the possible relationship between miR-942 levels and the pathogenesis of preeclampsia using in vitro assays and to investigate circulating miR-942 levels in the early phase of mid-of pregnancy in women who later developed preeclampsia and in women with uncomplicated pregnancies. Methods: Plasma samples were collected from pregnant women between 12 and 20 weeks of gestation. MiR-942 levels were determined by stem-loop real-time PCR for 26 cases who subsequently developed preeclampsia as well as for 52 controls. Bioinformatics software was used to predict the target genes of miR-942, and a dual-luciferase reporter system was utilized to validate target gene regulation. Finally, MTT proliferation assays, transwell invasion assays, and endothelial cell tube formation assays were performed to further explore the function of miR-942 using a human extravillous trophoblast cell line (TEV-1). Result: Circulating miR-942 levels were significantly lower in mid-pregnancy (12–20 weeks gestation) in women who later developed preeclampsia compared with those with an uncomplicated pregnancy (p < 0.05). Endoglin (ENG) is an miR-942 target gene. MiR-942 had a sensitivity of 0.673, a specificity of 0.875, and an area under the receiver operating characteristic curve (AUC) of 0.718 [95% CI, 0.594–0.822] for the possible screening of preeclampsia. In vitro, decreased miR-942 expression decreased the invasive ability of TEV-1 cells, and inhibited the HUVEC angiogenesis assay, both effects that are similar to what is observed in preeclampsia (both p Conclusion: MiR-942 may be involved in the pathogenesis of preeclampsia via the regulation of its target gene ENG. Multicenter studies must be performed and a greater number of samples must be analyzed to ascertain whether circulating miR-942 levels can serve as a novel early diagnostic marker for preeclampsia.
- Open Access
- 25 August 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (8) , e0161626
Plasma Level of Placenta-Derived Macrophage-Stimulating Protein -Chain in Preeclampsia before 20 Weeks of Pregnancy
This study aimed to investigate the diagnostic value of placenta-derived macrophage-stimulating protein α-chain (MSP-α) before the 20th week of gestation for the early diagnosis of preeclampsia (PE). Two parts of this nested case-control study were simultaneously executed, and 1500 pregnant women were recruited. A total of 124 pregnant women were included in the plasma analysis part of this study. The MSP-α plasma level was measured before the 20th week of gestation, and the participants were followed until delivery. A case group of 62 women with PE and a control group of 62 women matched by gestational age, maternal age, and pre-pregnancy BMI (with normotensive pregnancies) were evaluated. In the placenta analysis part of this nested case-control study, the placentas of 34 pregnant women were randomly obtained. The placental levels of MSP were measured in 17 individuals with PE (case group) and in 17 women with a normotensive pregnancy matched by gestational age and maternal age (control group). The plasma level of MSP-α was higher in the PE group than in the control group before the 20th week of gestation (p < 0.001). In addition, compared to the women with severe features in the PE group, those without severe features had a significantly higher plasma MSP-α level before the 20th week of gestation (p < 0.001). The area under the receiver operating characteristic curve (AUC) of MSP-α before the 20th week of gestation was 0.905 (95% CI, 0.811–0.962) for the women with early-onset PE without severe features. With regard to the placenta, the PE group (accumulated optical density, IOD [SUM] = 8862.37 ± 2064.42) exhibited increased MSP staining (more intense MSP staining or more extensive staining) compared with the control group (normal pregnancies (IOD [SUM] = 447.92 ± 114.72, P < 0.001). Furthermore, increased MSP staining was detected among the women without severe features compared with those with severe features in the PE group (IOD [SUM]: 12192.65 ± 5325.56 vs. 4104.83 ± 2383.06, P = 0.021). According to the findings of this study, the plasma level of MSP-α may be associated with PE, and MSP-α may be considered a candidate protein for further analysis in studies of PE. Multicenter studies with larger sample sizes must be performed in the future to obtain accurate results regarding the predictive value of MSP-α in combination with other protein factors for the early diagnosis of PE.
- 25 August 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (8) , e0161626
Open AccessPlasma Level of Placenta-Derived Macrophage-Stimulating Protein -Chain in Preeclampsia before 20 Weeks of Pregnancy
This study aimed to investigate the diagnostic value of placenta-derived macrophage-stimulating protein α-chain (MSP-α) before the 20th week of gestation for the early diagnosis of preeclampsia (PE). Two parts of this nested case-control study were simultaneously executed, and 1500 pregnant women were recruited. A total of 124 pregnant women were included in the plasma analysis part of this study. The MSP-α plasma level was measured before the 20th week of gestation, and the participants were followed until delivery. A case group of 62 women with PE and a control group of 62 women matched by gestational age, maternal age, and pre-pregnancy BMI (with normotensive pregnancies) were evaluated. In the placenta analysis part of this nested case-control study, the placentas of 34 pregnant women were randomly obtained. The placental levels of MSP were measured in 17 individuals with PE (case group) and in 17 women with a normotensive pregnancy matched by gestational age and maternal age (control group). The plasma level of MSP-α was higher in the PE group than in the control group before the 20th week of gestation (p < 0.001). In addition, compared to the women with severe features in the PE group, those without severe features had a significantly higher plasma MSP-α level before the 20th week of gestation (p < 0.001). The area under the receiver operating characteristic curve (AUC) of MSP-α before the 20th week of gestation was 0.905 (95% CI, 0.811–0.962) for the women with early-onset PE without severe features. With regard to the placenta, the PE group (accumulated optical density, IOD [SUM] = 8862.37 ± 2064.42) exhibited increased MSP staining (more intense MSP staining or more extensive staining) compared with the control group (normal pregnancies (IOD [SUM] = 447.92 ± 114.72, P < 0.001). Furthermore, increased MSP staining was detected among the women without severe features compared with those with severe features in the PE group (IOD [SUM]: 12192.65 ± 5325.56 vs. 4104.83 ± 2383.06, P = 0.021). According to the findings of this study, the plasma level of MSP-α may be associated with PE, and MSP-α may be considered a candidate protein for further analysis in studies of PE. Multicenter studies with larger sample sizes must be performed in the future to obtain accurate results regarding the predictive value of MSP-α in combination with other protein factors for the early diagnosis of PE.
- Open Access
- 5 February 2016
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 123 (13) , 2113-2118
Circular RNA in blood corpuscles combined with plasma protein factor for early prediction of pre‐eclampsia
Objective: To determine the expression of circular RNA (circRNA) in blood corpuscles of pregnant women before 20 weeks of pregnancy and to create a new model to identify the performance of circRNA combined with protein factors for the early diagnosis of pre‐eclampsia (PE).Design: Nested case–control study.Setting: University medical centre, Guangzhou, China.Population: A total of 1400 pregnant women recruited between 8 and 20 weeks of gestation. In all, 41 women with PE were included in the study, and were matched with 41 normally pregnant women based on maternal age and gestational age at same‐size ratio.Methods: The samples were analysed using a human circRNA microarray in the discovery phase, then the circRNA and the plasma protein factor endoglin (ENG) were validated. Finally we combined ENG with circRNA to create a new early prediction model for PE.Main outcome measures: Early changes of circRNA and ENG in PE.Results: The circ_101222 levels in blood corpuscles of patients with PE were significantly higher than those in corresponding healthy women (P < 0.001). Using ENG in combination with circ_101222 resulted in a sensitivity of 0.7073, a specificity of 0.8049, and overall area under the curve of 0.876 (95% confidence interval 0.816–0.922) for the prediction of PE.Conclusion: CircRNA and plasma proteins may have some predictive value for PE (such as circ_101222 and ENG). The performance of each of these factors may be strengthened when plasma proteins are used in combination with circRNA. The results are preliminary and need to be validated in larger studies and other populations.Tweetable Plasma protein endoglin in combination with circ_101222 strengthened the predictive power for pre‐eclampsia.
- 5 February 2016
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 123 (13) , 2113-2118
Open AccessCircular RNA in blood corpuscles combined with plasma protein factor for early prediction of pre‐eclampsia
Objective: To determine the expression of circular RNA (circRNA) in blood corpuscles of pregnant women before 20 weeks of pregnancy and to create a new model to identify the performance of circRNA combined with protein factors for the early diagnosis of pre‐eclampsia (PE).Design: Nested case–control study.Setting: University medical centre, Guangzhou, China.Population: A total of 1400 pregnant women recruited between 8 and 20 weeks of gestation. In all, 41 women with PE were included in the study, and were matched with 41 normally pregnant women based on maternal age and gestational age at same‐size ratio.Methods: The samples were analysed using a human circRNA microarray in the discovery phase, then the circRNA and the plasma protein factor endoglin (ENG) were validated. Finally we combined ENG with circRNA to create a new early prediction model for PE.Main outcome measures: Early changes of circRNA and ENG in PE.Results: The circ_101222 levels in blood corpuscles of patients with PE were significantly higher than those in corresponding healthy women (P < 0.001). Using ENG in combination with circ_101222 resulted in a sensitivity of 0.7073, a specificity of 0.8049, and overall area under the curve of 0.876 (95% confidence interval 0.816–0.922) for the prediction of PE.Conclusion: CircRNA and plasma proteins may have some predictive value for PE (such as circ_101222 and ENG). The performance of each of these factors may be strengthened when plasma proteins are used in combination with circRNA. The results are preliminary and need to be validated in larger studies and other populations.Tweetable Plasma protein endoglin in combination with circ_101222 strengthened the predictive power for pre‐eclampsia.
- 19 May 2015
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 292 (5) , 1043-1050
Maternal plasma TIMP-4 levels combined with clinical risk factors for the early prediction of pregnancy-induced hypertension
The objective of this study was to create a model for early predicting pregnancy-induced hypertension (PIH) using plasma markers and clinical risk factors. A nested case–control study was performed at the Laboratory Department of Guangzhou Women and Children’s Medical Center. From a prospective cohort of tens of thousands of unselected women with singleton pregnancies at 8–20 weeks gestation, maternal plasma samples were obtained from 73 women who subsequently developed PIH (PIH group) and 146 gestational age- and maternal age-matched women with normotensive pregnancies (control group). Proteins extracted from the plasma samples were screened by microchip and verified by ELISA. Clinical risk factor data were analyzed retrospectively. Compared to the control group, high concentrations of tissue inhibitor of metalloproteinase-4 (TIMP-4) were found in women with PIH (P = 0.000). Univariate risk factor analysis identified three variables with significant differences between the groups: family history of PIH (P = 0.031), body mass index (BMI; P < 0.001), and non-glucose-6-phosphate dehydrogenase deficiency-induced anemia (P < 0.027). Multiple regression analyses revealed a significant relationship of PIH with TIMP-4 levels, BMI, and family history (combined area under the receiver operating characteristic curve = 0.820). Upregulation of plasma TIMP-4 might contribute to PIH processes. Potential risk factors of this disease may include a family history of PIH and BMI. The combination of TIMP-4 levels and these risk factors may have some predictive values for PIH. Future multicenter studies including greater numbers of samples, analyzed proteins, and risk factors are needed to obtain a higher predictive value of the model for the clinical diagnosis of PIH.
- 19 May 2015
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 292 (5) , 1043-1050
Maternal plasma TIMP-4 levels combined with clinical risk factors for the early prediction of pregnancy-induced hypertension
The objective of this study was to create a model for early predicting pregnancy-induced hypertension (PIH) using plasma markers and clinical risk factors. A nested case–control study was performed at the Laboratory Department of Guangzhou Women and Children’s Medical Center. From a prospective cohort of tens of thousands of unselected women with singleton pregnancies at 8–20 weeks gestation, maternal plasma samples were obtained from 73 women who subsequently developed PIH (PIH group) and 146 gestational age- and maternal age-matched women with normotensive pregnancies (control group). Proteins extracted from the plasma samples were screened by microchip and verified by ELISA. Clinical risk factor data were analyzed retrospectively. Compared to the control group, high concentrations of tissue inhibitor of metalloproteinase-4 (TIMP-4) were found in women with PIH (P = 0.000). Univariate risk factor analysis identified three variables with significant differences between the groups: family history of PIH (P = 0.031), body mass index (BMI; P < 0.001), and non-glucose-6-phosphate dehydrogenase deficiency-induced anemia (P < 0.027). Multiple regression analyses revealed a significant relationship of PIH with TIMP-4 levels, BMI, and family history (combined area under the receiver operating characteristic curve = 0.820). Upregulation of plasma TIMP-4 might contribute to PIH processes. Potential risk factors of this disease may include a family history of PIH and BMI. The combination of TIMP-4 levels and these risk factors may have some predictive values for PIH. Future multicenter studies including greater numbers of samples, analyzed proteins, and risk factors are needed to obtain a higher predictive value of the model for the clinical diagnosis of PIH.
- Open Access
- 23 April 2015
- Published by New Century Science Press, LLC in 国际内分泌与代谢研究
- Vol. 2 (1) , 6
荆州区农村人口初发糖尿病胰岛功能的现状跟踪调查*
Objective: To study the change of islet function in patients with incipient diabetic characteristics through incipient diabetic tracking observation of the islet function in patients of Jingzhou area. Methods: Selection of 1220 cases of patients with diabetes mellitus in Jingzhou area as research object at the beginning, 12 months follow-up, the clinic after 3 months, 6 months and 12 months, all patients to detect blood sugar change, c-peptide release quantity, calculate insulin secretion index (HOMA -β) and insulin resistance index (HOMA IR), summarizes the characteristic of islet function in patients with changes. Results: ① The patients restored to basic standard blood sugar in 3 months by drug treatment, and the patient's blood glucose levels not seen obvious fluctuation after 6 months and 12 months; ② During follow-up, patients with diabetes sustained c-peptide release quantity reduction, and in three months after treatment, c-peptide release decreased obviously, and see a doctor at 6 months and 12 months after the comparison, the difference was statistically significant (P < 0.05). ③ During follow-up, insulin capacity was decreasing among patients with diabetes, within three months after the doctor had the greatest reduction, the difference was statistically significant (P < 0.05); ④ During follow-up, island hormone decreasing index, insulin resistance index continued to rise among patients with diabetes, and 6 months and 12 months, the most significant variations in 3 months (P < 0.05). Conclusion: With the extension of course, the pancreatic islet function in patients with early onset diabetes decreased gradually. It could be proved that there is a significant correlation between the two and especially seen in obvious function decline of pancreatic islets among the patients within 3 months.
- 23 April 2015
- Published by New Century Science Press, LLC in 国际内分泌与代谢研究
- Vol. 2 (1) , 6
Open Access荆州区农村人口初发糖尿病胰岛功能的现状跟踪调查*
Objective: To study the change of islet function in patients with incipient diabetic characteristics through incipient diabetic tracking observation of the islet function in patients of Jingzhou area. Methods: Selection of 1220 cases of patients with diabetes mellitus in Jingzhou area as research object at the beginning, 12 months follow-up, the clinic after 3 months, 6 months and 12 months, all patients to detect blood sugar change, c-peptide release quantity, calculate insulin secretion index (HOMA -β) and insulin resistance index (HOMA IR), summarizes the characteristic of islet function in patients with changes. Results: ① The patients restored to basic standard blood sugar in 3 months by drug treatment, and the patient's blood glucose levels not seen obvious fluctuation after 6 months and 12 months; ② During follow-up, patients with diabetes sustained c-peptide release quantity reduction, and in three months after treatment, c-peptide release decreased obviously, and see a doctor at 6 months and 12 months after the comparison, the difference was statistically significant (P < 0.05). ③ During follow-up, insulin capacity was decreasing among patients with diabetes, within three months after the doctor had the greatest reduction, the difference was statistically significant (P < 0.05); ④ During follow-up, island hormone decreasing index, insulin resistance index continued to rise among patients with diabetes, and 6 months and 12 months, the most significant variations in 3 months (P < 0.05). Conclusion: With the extension of course, the pancreatic islet function in patients with early onset diabetes decreased gradually. It could be proved that there is a significant correlation between the two and especially seen in obvious function decline of pancreatic islets among the patients within 3 months.